USA flag logo/image

An Official Website of the United States Government

Nanocapsules for transposon therapy in cancer

Award Information

Agency:
Department of Defense
Branch:
Army
Award ID:
73700
Program Year/Program:
2005 / SBIR
Agency Tracking Number:
A043-181-0165
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
GENESEGUES, INC.
GENESEGUES, INC. 3180 HIGH POINT DRIVE CHASKA, MN 55318-9476
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: Nanocapsules for transposon therapy in cancer
Agency / Branch: DOD / ARMY
Contract: W81XWH-05-C-0084
Award Amount: $69,883.00
 

Abstract:

Viral vectors are used in more than 70% of current gene therapy trials. However, immunogenicity, oncogenicity, and poor tumor transfection efficiencies present significant barriers to clinical success. Sleeping Beauty Transposon (SBT) technology, combined with a targeted, tumor-penetrating, non-viral gene transfer system, offers an alternative approach for therapeutic transgene production with low toxicity. We have developed a non-viral, sub-50 nm capsule formulation platform that condenses and encapsulates macromolecules in protein/peptide capsules for targeted drug delivery. In vitro, we have demonstrated nanocapsule uptake is receptor-mediated via caveolae, supporting the possibility of efficient tumor-targeting and intracellular delivery. In vivo, we have demonstrated the potential of nanocapsules for systemic, targeted, tumor-penetrating delivery of oligonucleotides, and produced expression of SBT plasmids for reporter and therapeutic genes. We propose to demonstrate feasibility of nanoencapsulated SBT plasmids for use in targeted treatment of advanced prostate cancer, by comparing the biodistribution of three nanocapsule coating proteins for tumor-targeting in a syngeneic, orthotopic model of prostate cancer. We will select the most promising coating for future testing with a transposon plasmid being developed to generate siRNA against hyaluronan receptors CD44 and RHAMM-1, which have been shown to play major roles in prostate cancer metastasis and tumor survival.

Principal Investigator:

Gretchen Unger
CSO
9524433798
gmu@genesegues.com

Business Contact:

Robert Unger
CFO
9524433798
rtu@genesegues.com
Small Business Information at Submission:

GENESEGUES, INC.
3180 High Point Chaska, MN 55318

EIN/Tax ID: 411955104
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No